New Data, New Opportunities, and New Clinical Challenges Using Immunotherapies for TNBC

Join us for this live Webinar held during SABCS 2020 to hear how a panel of breast cancer experts leverage immune-targeted therapies to better manage early-stage through metastatic TNBC! Learn how to use immune checkpoint inhibitor–based combinations and manage immune-related adverse events in your patients with breast cancer, then get up to date on key clinical trials assessing new immune-targeted therapies in TNBC.

During this live Webinar, you will have many opportunities to engage with the faculty through interactive patient case scenarios and dynamic panel discussions, along with an audience question and answer session.

2020 San Antonio Breast Cancer Symposium

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


  • Welcome and Introduction
  • Immune Checkpoint Inhibitor in Advanced TNBC
    Rita Nanda, MD
  • Immune Checkpoint Inhibitor in Early-Stage TNBC
    Heather McArthur, MD, MPH
  • Understanding Immune-Related Adverse Events
    Heather McArthur, MD, MPH, and Rita Nanda, MD
  • Antibody–Drug Conjugates in TNBC
    Kevin Kalinsky, MD
  • Panel Discussion and Audience Question & Answer Session


Date / Time
Event Details


Program Director
Heather McArthur, MD, MPH

Associate Professor
Department of Medicine
Komen Distinguished Chair in Clinical Breast Cancer
Clinical Director Breast Cancer Program
Harold C. Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Dallas, Texas

Kevin Kalinsky, MD, MS

Director, Glenn Family Breast Center
Hematology and Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Rita Nanda, MD

Associate Professor of Medicine
Breast Oncology
Section of Hematology/Oncology
Department of Medicine
The University of Chicago
Chicago, Illinois

Goal Statement
The goal of this activity is to improve the competence and performance of learners to integrate immune checkpoint inhibitors into the treatment of triple-negative breast cancer.

Target Audience
This program is intended for oncologists and other healthcare providers who care for patients with triple-negative breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate available data on the use of ICI-based combinations as part of neoadjuvant/adjuvant therapy for early-stage triple-negative breast cancer
  • Plan first-line treatment with ICI-based therapy for individual patients with locally advanced or metastatic triple-negative breast cancer
  • Apply clinical evidence and expert recommendations on immune-targeted therapies with progressive triple-negative breast cancer after 1 or more previous lines of therapy
  • Manage specific treatment-related complications associated with the use of immune checkpoint inhibitors in patients with breast cancer
  • Recommend ongoing clinical trials assessing new therapeutic approaches for appropriate patients with triple-negative breast cancer


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.